Antibody treatment of lower respiratory tract infections

Seminars in Respiratory Infections

Volumn 16, Issue 1, 2001, Pages 67-75

  Skerrett, Shawn J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; GAMIMMUNE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANTIGEN SPECIFICITY; DRUG EFFECT; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; MUCOCILIARY CLEARANCE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0035075248     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2001.22730     Document Type: Review

References (64)

1. Intravenous immunoglobulins as therapeutic agents
2. Return to the past: The case for antibody-based therapies in infectious diseases
3. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XI. The use of concentrated normal human serum gamma globulin (human serum globulin) in the prophylaxis and treatment of measles
4. Current perspectives on the use of intravenous immunoglobulin
5. Host defenses against respiratory infection
6. The use of intravenous immune globulin in immunodeficiency diseases
7. Newer uses of intravenous immunoglobulins as anti-infective agents
8. The primary immunodeficiencies (1)
9. The primary immunodeficiencies. (2)
10. The primary immunodeficiencies
11. Immunoglobulin deficiences and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia
12. The role of the spleen in resistance to infection
13. Immunologic reconstitution after human marrow grafting
14. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives
15. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients
16. Frustration and foundation. Management of pneumonia before antibiotics
17. Serum therapy revisited: Animal models of infection and development of passive antibody therapy
18. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia
19. IgG antibody reactive with five serotypes of Streptococcus pneumoniae in commercial intravenous immunoglobulin preparations
20. 2 fragments administered intranasally
21. Efficacy of intravenous immune globulin for treatment of experimental Pseudomonas aeruginosa pneumonia
22. Adjuvant therapy with pseudomonas immunoglobulin in artificially ventilated patients at a surgery intensive care unit
23. Supplemental immune globulins in sepsis
24. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations of cystic fibrosis
25. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis
26. Polyclonal and monoclonal antibody therapy for experimental P. aeruginosa pneumonia
27. Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody
28. Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia
29. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients
30. Pharmacokinetics, tolerability, and preliminary efficacy of human anti-Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients
31. Specific immunoglobulin for treatment of whooping cough
32. Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model
33. Protective activities in mice of monoclonal antibodies against pertussis toxin
34. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - A comparative observational study
35. Intravenous immune globulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens
36. Passive local immunotherapy of experimental staphylococcal pneumonia with human intravenous immunoglobulin
37. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection
38. Effect of adjuvant immunoglobulin therapy on infections in patients in an surgical intensive care unit. Results of a randomized controlled study
39. Intravenous immunoglobulins in association with antibiotics: A therapeutic trial in septic intensive care unit patients
40. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater
41. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli
42. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial
43. Treatment of gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial
44. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group
45. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group
46. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group
47. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group
48. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
49. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients
50. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
51. Immunoglobulin administration and ribavirin therapy: Efficacy in respiratory syncytial virus infection of the cotton rat
52. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients
53. Respiratory syncytial virus immune globulin intravenous: Indications for use
54. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group
55. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children
56. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
57. An outbreak of respiratory syncytial virus in a bone marrow transplant center
58. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin
59. Respiratory syncytial virus infection in adult BMT recipients: Effective therapy with short duration nebulised ribavirin
60. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - A compassionate use experience
61. Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection
62. Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin
63. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention
64. The current status of bacteremic pneumococcal pneumonia. Re-evaluation of an underemphasized problem